“Based on the results we have generated to-date, MBP8298 appears to have the potential to fundamentally alter the course of this devastating disease,” said Kevin Giese, president and CEO of BioMS. “The population in Finland suffers disproportionately from multiple sclerosis and like BioMS is committed to the development of an effective treatment.”
The trial is study enrolling approximately 553 patients who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a significant increase in the time to progression of the disease as measured. To date the trial has successfully passed five safety reviews by its independent Data Safety Monitoring Board.